Literature DB >> 28356370

Comorbidities in the management of patients with lung cancer.

Charlotte Leduc1, Delphine Antoni2, Anne Charloux3, Pierre-Emmanuel Falcoz4, Elisabeth Quoix5.   

Abstract

Lung cancer represents a major public health issue worldwide. Unfortunately, more than half of them are diagnosed at an advanced stage. Moreover, even if diagnosed early, diagnosis procedures and treatment can be difficult due to the frequent comorbidities observed in these patients. Some of these comorbidities have a common major risk factor, i.e. smoking, whereas others are unrelated to smoking but frequently observed in the general population. These comorbidities must be carefully assessed before any diagnostic and/or therapeutic decisions are made regarding the lung cancer. For example, in a patient with severe emphysema or with diffuse lung fibrosis, transthoracic needle biopsy can be contraindicated, meaning that in some instances a precise diagnosis cannot be obtained; in a patient with chronic obstructive pulmonary disease, surgery may be impossible or should be preceded by intensive rehabilitation; patients with interstitial lung disease are at risk of radiation pneumonitis and should not receive drugs which can worsen the respiratory insufficiency. Patients who belong to what are called "special populations", e.g. elderly or HIV infected, should be treated specifically, especially regarding systemic treatment. Last but not least, psychosocial factors are of great importance and can vary from one country to another according to health insurance coverage.
Copyright ©ERS 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28356370     DOI: 10.1183/13993003.01721-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  20 in total

1.  How can counselling by family physicians on nutrition and physical activity be improved: trends from a survey in Germany.

Authors:  S J Boesenecker; V Mathies; J Buentzel; J Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-06       Impact factor: 4.322

2.  Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC.

Authors:  Johannes Noé; Walter Bordogna; Venice Archer; Vlatka Smoljanovic; Magalie Hilton; Ryan Woodhouse; Simonetta Mocci; Shirish M Gadgeel
Journal:  JTO Clin Res Rep       Date:  2022-05-18

3.  The Shared Genetic Architectures Between Lung Cancer and Multiple Polygenic Phenotypes in Genome-Wide Association Studies.

Authors:  Jinyoung Byun; Younghun Han; Quinn T Ostrom; Jacob Edelson; Kyle M Walsh; Rowland W Pettit; Melissa L Bondy; Rayjean J Hung; James D McKay; Christopher I Amos
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-03-26       Impact factor: 4.090

4.  Psychosocial consequences of diagnosis and treatment of lung cancer and evaluation of the need for a lung cancer specific instrument using focus group methodology.

Authors:  Milou Looijmans; Annick S van Manen; Marjan J Traa; Jeroen S Kloover; Bart L J Kessels; Jolanda de Vries
Journal:  Support Care Cancer       Date:  2018-06-09       Impact factor: 3.603

5.  Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.

Authors:  Steven D Criss; Lauren Palazzo; Tina R Watson; Adelle M Paquette; Keith Sigel; Juan Wisnivesky; Chung Yin Kong
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

6.  A comprehensive algorithm to distinguish between MPLC and IPM in multiple lung tumors patients.

Authors:  Jun Shao; Chengdi Wang; Jingwei Li; Lujia Song; Linhui Li; Panwen Tian; Weimin Li
Journal:  Ann Transl Med       Date:  2020-09

7.  Lotus leaf flavonoids induce apoptosis of human lung cancer A549 cells through the ROS/p38 MAPK pathway.

Authors:  Xiang-Bo Jia; Quan Zhang; Lei Xu; Wen-Jian Yao; Li Wei
Journal:  Biol Res       Date:  2021-03-02       Impact factor: 5.612

8.  Does Delaying Time in Cancer Treatment Affect Mortality? A Retrospective Cohort Study of Korean Lung and Gastric Cancer Patients.

Authors:  Kyu-Tae Han; Woorim Kim; Seungju Kim
Journal:  Int J Environ Res Public Health       Date:  2021-03-26       Impact factor: 3.390

9.  Should we screen patients for carotid artery disease before lung cancer resection?

Authors:  Anne Charloux; Cézar Matau; Jérémie Jégu; Olivier Rouyer; Pierre-Emmanuel Falcoz; Elisabeth Quoix
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

10.  A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy in inoperable stage I non-small cell lung cancer.

Authors:  Can Li; Li Wang; Qian Wu; Jiani Zhao; Fengming Yi; Jianjun Xu; Yiping Wei; Wenxiong Zhang
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.